TP53 and cancer: Mutation of an additional acetylation site at the backdrop of p53 3KR mutant markedly attenuated p53’s capability to suppress tumor formation, repress SLC7A11 expression, and induce ferroptosis in cancer cells (Wang et al., 2016).